用深度转移学习来诊断阿尔茨海默病的可解释的人工智能范式
Tanjim Mahmud1, Koushick Barua1, Sultana Umme Habiba2
1Department of Computer Science and Engineering, Rangamati Science and Technology University, Rangamati 4500, Bangladesh.
Diagnostics (Basel, Switzerland)
|February 10, 2024
概括
这项研究引入了一种可解释的AI (XAI) 方法,用于使用深度学习和集合模型诊断阿尔茨海默病. 新的XAI模型达到96%的准确性,为临床决策提供视觉洞察力.
科学领域:
- 人工智能的人工智能
- 神经科学是一个神经科学.
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响全球数百万人,需要早期和准确的诊断才能有效管理.
- 深度学习在分析AD诊断神经成像方面表现有前途,但缺乏可解释性限制了临床信任和采用.
- 可解释的人工智能 (XAI) 对于了解医疗保健中的人工智能决策过程至关重要.
研究的目的:
- 为阿尔茨海默病的诊断开发一个可解释的人工智能 (XAI) 基础的框架.
- 提高AD医疗图像分析中的深度学习模型的可解释性和透明度.
- 提高临床信任和接受AI工具在AD诊断中的AI工具.
主要方法:
- 通过预训练的卷积神经网络 (CNN) 进行深度转移学习,包括VGG16,VGG19,DenseNet169和DenseNet201.
- 开发了组合模型 (组合-1:VGG16/VGG19,组合-2:DenseNet169/DenseNet201) 以提高诊断性能.
- 整合了XAI技术,特别是突出度地图和梯度加权类激活映射 (grad-CAM),进入了一个新的诊断模型.
主要成果:
- 评估了个别的CNN模型,合奏表现出卓越的表现.
- 组合模型达到高达95%的准确性,精度,回忆和F1分数.
- 新的XAI集成模型显示了96%的惊人的准确性,为诊断推理提供了视觉洞察力.
结论:
- 将深度转移学习与XAI技术相结合,为阿尔茨海默病诊断提供了一种强大的方法.
- 开发的XAI框架提高了模型的解释性,为临床决策支持提供了可视证据.
- 这项研究为在神经退行性疾病诊断中更加透明,可信和临床适用的AI模型铺平了道路.
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189


